Cite
APA Citation
Barr, P. M., Smith, S. D., Roschewski, M. J., O'Brien, S. M., Sharman, J. P., Melear, J. M., Patel, P., Calvo, R., Yang, H., & Spurgeon, S. E. (2022). phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Leukemia & lymphoma, 63(7), 1728–1732. http://access.bl.uk/ark:/81055/vdc_100159167102.0x000029